Erlotinib Versus Standard Chemotherapy As First-Line Treatment For European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial

·2012·DOI
Health Sciences and Innovation
Biomedical Engineering
Cancer Research and Treatment
Research on Non-Small Cell Lung Cancer

Role in the Field

Neutralin Health Sciences and Innovation
Neutralin Biomedical Engineering
Neutralin Cancer Research and Treatment
Neutralin Research on Non-Small Cell Lung Cancer

Abstract

Citations

4,554

Year

2012

PageRank

4.6 / 10

Relative influence (log-scaled)

Erlotinib Versus Standard Chemotherapy As First-Line Treatment For European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial | Manumap